Physician profile
Patrick Whelan
NPI 1851704639
$113,856.94
in general payments reported to CMS, 2019-2025
43 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2021: $1,459 · 2022: $1,961 · 2023: $2,996 · 2024: $21K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $75K · Consulting Fee: $6,197 · Food and Beverage: $3,378 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $75,333.33 |
| Consulting Fee | $6,197.00 |
| Food and Beverage | $3,378.37 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $75,333.33 | 2024-2025 | Nanoknife |
| Boston Scientific Corporation | $25,429.42 | 2019 | |
| Ambu INC. | $8,139.14 | 2021-2024 | |
| Janssen Biotech, INC. | $719.47 | 2021-2025 | Erleada |
| Abbvie INC. | $698.99 | 2022-2024 | Botox, Lupron Depot |
| Pfizer INC. | $389.25 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $270.65 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $237.27 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $216.04 | 2022 | |
| Astellas Pharma US INC | $214.64 | 2021-2025 | Xtandi, Veozah |
| Progenics Pharmaceuticals, INC. | $212.33 | 2022-2025 | |
| Medtronic, INC. | $191.47 | 2022-2023 | Interstim |
| Abbott Laboratories | $147.97 | 2024 | Aveir |
| Merck Sharp & Dohme LLC | $134.94 | 2022-2025 | Lynparza, Keytruda, Welireg |
| Antares Pharma, INC. | $111.21 | 2021-2025 | Xyosted, Tlando, Nocdurna |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $109.81 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $108.73 | 2021-2023 | Aveed, Xiaflex |
| Myovant Sciences INC. | $104.33 | 2021-2022 | |
| Conmed Corporation | $103.67 | 2022 | |
| Myriad Genetic Laboratories, INC. | $101.87 | 2021-2024 | Prolaris |
| Accord Healthcare, INC. | $92.74 | 2023-2025 | |
| Urogen Pharma, INC. | $88.88 | 2023-2025 | Jelmyto |
| Tempus Ai, INC | $88.83 | 2024-2025 | Xt Cdx |
| Intuitive Surgical, INC. | $83.34 | 2022 | |
| Novo Nordisk INC | $61.72 | 2024-2025 | Rivfloza |
| Amgen INC. | $52.20 | 2021-2023 | Prolia |
| Blue Earth Diagnostics | $47.10 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $43.91 | 2023-2025 | |
| Olympus America INC. | $41.90 | 2023 | Itind System |
| Coloplast Corp | $31.32 | 2023-2024 | Porges Coloplast |
| Urovant Sciences INC | $27.52 | 2022 | |
| Dendreon Pharmaceuticals LLC | $24.07 | 2022 | |
| Axonics, INC. | $23.59 | 2022 | |
| Allergan, INC. | $20.49 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $19.61 | 2021 | |
| Immunitybio, INC. | $19.36 | 2025 | |
| Endo USA, INC. | $19.05 | 2024 | Xiaflex, Aveed |
| Halozyme INC | $18.55 | 2023 | |
| Hollister Incorporated | $17.09 | 2023 | Vapro, Infyna Chic |
| Acerus Pharmaceuticals Corporation | $16.81 | 2022 | |
| 180 Medical, INC. | $16.57 | 2024 | Cure Catheter |
| Innovation Technologies INC | $15.30 | 2025 | Irrisept |
| Foundation Medicine, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Whelan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.